Evidence map›Paper›PMID 33219865›Full record

ArticleActa neurochirurgica2021

Incidence and prognosis of distant metastasis in malignant peripheral nerve sheath tumors.

Yao Xu, Guijun Xu, Zheng Liu, Jincai Duan, Yile Lin, Jiajia Zhu, Vladimir P Baklaushev, Vladimir P Chekhonin, Karl Peltzer, Guowen Wang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neurochirurgica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Brain metastases of sarcoma: a rare phenomenon in rare tumours.Journal of cancer research and clinical oncology · 2023
    Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yao XuDepartment of Bone and Soft Tissue Tumors, Key Laboratory of Cancer Prevention, Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin, 300060, China.
Guijun XuDepartment of Bone and Soft Tissue Tumors, Key Laboratory of Cancer Prevention, Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin, 300060, China.
Zheng LiuDepartment of Bone and Soft Tissue Tumors, Key Laboratory of Cancer Prevention, Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin, 300060, China.
Jincai DuanDepartment of Bone and Soft Tissue Tumors, Key Laboratory of Cancer Prevention, Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin, 300060, China.
Yile LinDepartment of Bone and Soft Tissue Tumors, Key Laboratory of Cancer Prevention, Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin, 300060, China.
Jiajia ZhuDepartment of Bone and Soft Tissue Tumors, Key Laboratory of Cancer Prevention, Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin, 300060, China.
Vladimir P BaklaushevFederal Research and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Biomedical Agency of the Russian Federation, Moscow, Russian Federation.
Vladimir P ChekhoninDepartment of Basic and Applied Neurobiology, Federal Medical Research Center for Psychiatry and Narcology, Moscow, Russian Federation.
Karl PeltzerDepartment of Research and Innovation, University of Limpopo, Turfloop, South Africa.
Guowen WangDepartment of Bone and Soft Tissue Tumors, Key Laboratory of Cancer Prevention, Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin, 300060, China.
Xin WangDepartment of Epidemiology and Biostatistics, First Affiliated Hospital, Army Medical University, Chongqing, China.
Chao ZhangDepartment of Bone and Soft Tissue Tumors, Key Laboratory of Cancer Prevention, Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin, 300060, China. drzhangchao@tmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant peripheral nerve sheath tumors (MPNSTs) are a type of soft tissue sarcomas (STS) with recurrence and metastatic potential. We aimed to investigate the risk factors for developing distant metastases (DM) and to identify the prognostic factors in patients with DM.

methodsBased on the Surveillance, Epidemiology, and End Result (SEER) database, MPNST patients diagnosed between 2010 and 2016 were extracted in our study. The logistic regression model was performed for predicting DM development while the Cox proportional hazard regression model was conducted for revealing the prognostic factors.

resultsEventually, 764 patients diagnosed with MPNSTs were included with 109 cases presenting with metastases at initial diagnosis. Larger tumor size and lymph node metastases were independent risk factors for developing DM. The median overall survival (OS) for patients with metastases was 8.0 (95% CI: 6.1-9.9) months. Multiple metastatic sites and no surgical treatment were prognostic factors for worse survival. Tumors located in non-head and neck region were related with better survival.

conclusionsThe incidence of DM was 14.3% with a dismal median OS of 8.0 months for metastatic MPNSTs. More evaluation should be applied for patients with large tumor size and lymph metastases. Tumors located in head and neck region and the presence of multiple metastases predicted worse survival outcome. Surgical treatment can significantly improve the survival of MPNST patients with distant metastasis.

Indexed as

AdultFemaleHead and Neck NeoplasmsHumansIncidenceLogistic ModelsMaleMiddle AgedNeoplasm Recurrence, LocalNeurofibrosarcomaPrognosisRisk FactorsSEER ProgramSoft Tissue NeoplasmsUnited StatesYoung AdultDistant metastasesMalignant peripheral nerve sheath tumorsPredictionSEER program

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.